Request Demo

Last update 23 Mar 2026

Lutetium (177 Lu) Vipivotide Tetraxetan

Last update 23 Mar 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals

Synonyms

177-Lutetium-PSMA-617(RadioMedix, Inc.), [Lu-177] vipivotide tetraxetan, Lu-177-PSMA-617 Lutetium-177-PSMA-617

+ [15]

Target

PSMA

Action

inhibitors

Mechanism

PSMA inhibitors(Prostate-specific membrane antigen inhibitors)

Therapeutic Areas

NeoplasmsUrogenital DiseasesDigestive System Disorders+ [2]

Active Indication

PSMA-Positive Castration-Resistant Prostatic CancerHormone-dependent prostate cancerMetastatic Prostate Carcinoma+ [17]

Inactive Indication-

Originator Organization

RadioMedix, Inc.

Active Organization

Novartis Pharma AG

Novartis Pharmaceuticals Corp.

Novartis Pharmaceuticals Canada, Inc.

+ [13]

Inactive Organization-

License Organization

China Isotope & Radiation Corp.

Endocyte, Inc.

HTA Co., Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (23 Mar 2022),

PSMA-Positive Castration-Resistant Prostatic Cancer

RegulationBreakthrough Therapy (United States), Priority Review (China), Orphan Drug (South Korea)

Structure/Sequence

Molecular FormulaC49H68LuN9O16

InChIKeyRSTDSVVLNYFDHY-NLQOEHMXSA-K

CAS Registry1703749-62-5

Boost your research with our ADC technology data.

view full example data

Clinical Trials associated with Lutetium (177 Lu) Vipivotide Tetraxetan

NCT06959433

/ Not yet recruitingPhase 3IIT

Safety and Efficacy of Lu-177 PSMA Treatment in Metastatic Clear Cell Renal Carcinoma

Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs. It is reported that 20-30% of RCCs are metastatic at the diagnosis and 5 years survival is approximately is 10-20% in this group of patients. Moreover, 60% of patients who are not metastatic at the diagnosis, develop metastates within 2-3 years. 2nd and 3th line effective treatment option in metastatic RCCs patients has been a subject of interest.
PSMA (protatate specific membrane antigen) with the other name glutamate carboxypeptidase, is a transmembrane protein and overexpresses in prostate adenocarcinomas and neoangiogenesis spots of endothelium of other several tumor types. It infronts as a target for theranostic consept for mainly prostate cancer in nuclear medicine. As a radionuclide treatment option, Lu-177 PSMA treatment is proved as safe and effective treatment option in castration resistant prostata cancer patients. After its widely use in prostate cancer, it is reported that PSMA molecule can be used for imaging of RCC patients and PSMA uptake is higher than 18F-FDG. For this reason, Lu-177 PSMA treatment can be a systemic treatment option in RCC patients who have progress afer 1st cycle treatment. In this study we aimed to safety and efficacy of Lu-177 PSMA treatment in metastatic RCC patients as systemic radionuclide treatment option.

Start Date01 May 2026

Sponsor / Collaborator

Ankara University

NCT07145177

/ RecruitingPhase 1IIT

A Phase 1b Study of 177Lu-PSMA-617 Combined With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.

Start Date16 Mar 2026

Sponsor / Collaborator

The University of California, San Francisco

[+1]

NCT07219147

/ RecruitingPhase 1IIT

Pilot Study of ¹⁷⁷Lu-PSMA-617 in Combination With Sipuleucel-T in Patients With Metastatic Castration-Resistant Prostate Cancer

This phase I trial compares the effect of lutetium Lu 177 (177^Lu)-prostate-specific membrane antigen (PSMA)-617 in combination with Sipuleucel-T to 177^Lu-PSMA-617 alone in treating patients with prostate that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow and spread despite surgical or medical intervention to block androgen production (castration-resistant). 177^Lu-PSMA-617, a type of radioconjugate, binds to a protein called PSMA, which is found on some prostate tumor cells. It gives off radiation that may kill the tumor cells. Sipuleucel-T, a type of vaccine and a type of cellular adoptive immunotherapy, is made from immune system cells. The cells are treated with a protein that is made by combining a protein found on prostate tumor cells with a growth factor. When the cells are injected back into the patient, they may stimulate T cells to kill prostate tumor cells. Giving 177^Lu-PSMA-617 in combination with sipuleucel-T may be safe, tolerable, and/or effective compared to 177^Lu-PSMA-617 alone in treating patients with metastatic castration-resistant prostate cancer.

Start Date05 Mar 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Translational Medicine associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Patents (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

671

Literatures (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

01 Apr 2026·CLINICAL NUCLEAR MEDICINE

Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration

Article

Author: Dewaraja, Yuni K. ; Wong, Ka Kit ; Roseland, Molly E. ; Fitzpatrick, Kellen J. ; Suresh, Krithika ; Frey, Kirk A. ; Viglianti, Benjamin L. ; Lu, Zhonglin

Purpose::

Prostate cancer treatment with 177 Lu-PSMA-617 depends on specific binding to the PSMA protein. If receptors become saturated by the radioligand, the uptake of the drug may be affected. Our goal was to measure the pharmacological effect of standard 7.4 GBq (200 mCi) administration of 177 Lu-PSMA-617 based on the uptake of 68 Ga-PSMA-11 on subsequent PET.

Patients and Methods::

We performed 68 Ga-PSMA-11 PET/CT within 0.5–75 hours after cycle 1 of therapy administration in 6 patients with metastatic castrate-resistant prostate cancer who volunteered for imaging. SUV mean of tumors (N=27) and organs, stratified by early (<2 h) and late (~3 d) post-therapy PET imaging, were compared with baseline PET.

Results::

There were large decreases in SUV mean for tumor, kidney, parotid gland, and liver among patients imaged early after therapy, with an average change in tumor SUV of −45% (95% CI: −66% to −25%; P <0.001). In contrast, only mild persistent declines in SUV were observed in those scanned late, with an average change in tumor SUV of −9% (95% CI: −33% to 16%; P =0.42).

Conclusions::

There are measurable decreases in PSMA binding following 177 Lu-PSMA-617 that resolve over time. As trials consider alternative therapeutic strategies, increasing dosage per cycle alone may not proportionally increase tumor uptake. Our findings warrant validation with a larger number of subjects, standardized post-therapy scan timing, and advanced pharmacokinetic analyses.

01 Mar 2026·Clinical Genitourinary Cancer

Treatment Discontinuation in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Lutetium-177 (177Lu)–PSMA-617: A Retrospective Real-World Study

Article

Author: Divband, Ghasemali ; Aryana, Kamran ; Sahafi, Pegah ; Askari, Emran ; Samadi, Mohammad Hadi ; Shamshirgaran, Amirreza ; Elahifard, Haniye

BACKGROUND:

Despite the efficacy of Lutetium-177 (¹⁷⁷Lu)-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer (mCRPC), high discontinuation rates limit its therapeutic potential. This study aimed to characterize discontinuation reasons, timing, predictive factors, and survival impact in a real-world cohort.

METHODS:

We retrospectively analyzed 208 mCRPC patients treated with ¹⁷⁷Lu-PSMA-617 between 2017 and 2024. Discontinuation was defined as cessation before 6 cycles. Reasons were categorized as disease progression, serious adverse events, patient-related factors, physician decision, death, or miscellaneous. Early discontinuation was defined as < 3 cycles. Logistic regression and Cox models identified predictors of discontinuation and overall survival (OS).

RESULTS:

Median cycles received were 3 (IQR 2-5); 169 patients (81.2%) discontinued, with 92 (44.2%) early discontinuation. Disease progression (43.8%) and serious adverse events (21.9%) were leading causes. Multivariate analysis revealed baseline creatinine (OR 5.50, P = .050) and ALP (per 100 U/L; OR 1.12, P = .032) predicted overall discontinuation, while Gleason score (OR 2.11, P = .009), hemoglobin (OR 0.62, P < .001), and platelet counts (OR 0.54, P = .004) predicted early discontinuation. Median OS was 13 months overall, 11 months in discontinuers versus 22 months in completers (P < .001), and 5 vs. 20 months in early vs. nonearly groups (P < .001). Treatment discontinuation (HR 1.95, P = .001) and hemoglobin (HR 0.68, P < .001) independently predicted OS.

CONCLUSION:

Over 80% of mCRPC patients discontinued ¹⁷⁷Lu-PSMA-617, driven by progression and toxicity, with early discontinuation linked to aggressive disease and poor hematologic reserve. Discontinuation independently worsens survival, emphasizing the need for careful selection and supportive interventions to improve adherence and outcomes.

01 Mar 2026·Revista espanola de medicina nuclear e imagen molecular

Predictive value of metastatic distribution patterns on [68Ga]Ga-PSMA PET/CT for [177Lu]Lu-PSMA therapy

Article

Author: Elboga, U ; Cayirli, Y B ; Dogan, I

OBJECTIVE:

This study aimed to assess the predictive value of metastatic distribution patterns on ⁶⁸Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

MATERIALS AND METHODS:

A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment ⁶⁸Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression. Whole-body PET/CT segmentation was performed using METAVOL software. Treatment response was classified using RECIP 1.0 criteria, and predictive values were analyzed using SPSS 22.0, with statistical significance set at p < 0.05.

RESULTS:

Based on RECIP 1.0 criteria, 58.3% (n = 28) responded to therapy, while 41.7% (n = 20) did not. Disease progression was observed in 29.2% (n = 14), and 70.8% (n = 34) showed no progression. Molecular response was significantly associated with parotid SUVmean (OR = 1.137, p = 0.047) and highest miM1 stage (OR = 0.241, p = 0.046). Molecular progression was significantly associated with lymph node metastasis (OR = 0.144, p = 0.006), bone-only metastasis (OR = 4.333, p = 0.030), ln/metTL-PSMA ratio (OR = 0.070, p = 0.042), b/metTL-PSMA ratio (OR = 13.085, p = 0.040), and TL-PSMA-based lymph node dominance over bone metastases (OR = 0.385, p = 0.044).

CONCLUSION:

This study highlights the predictive value of metastatic burden distribution on ⁶⁸Ga-PSMA PET/CT in determining treatment outcomes of ¹⁷⁷Lu-PSMA therapy.

455

News (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

18 Mar 2026

·www.fiercepharma.com

Gates-backed TerraPower Isotopes blueprints $450M plant to supply next wave of radiopharmaceuticals

A new TerraPower Isotopes site in Pennsylvania will be built out across 250,000 square feet and is expected to commence production in 2029. As interest in the cancer-fighting potential of radiopharmaceutical drugs continues to swell, companies have unleashed a spate of investments in recent years to manufacture the nuclear medicines and secure supplies of the radioactive isotopes underpinning them. Now, Bill Gates-founded TerraPower Isotopes (TPI)—which produces actinium-225 (ac-225) derived from legacy U.S. nuclear material—is laying out nearly half a billion dollars as it seeks to become the “premier global distributor” of the rare and promising ingredient. TPI on Wednesday unveiled plans to build a flagship ac-225 manufacturing facility in Philadelphia’s Bellwether District. The upcoming East Coast plant, backed by a $450 million investment, will join another U.S. TPI site in Everett, Washington, where the company said it is expanding capacity as well. The new site in Pennsylvania will be built out across 250,000 square feet and is expected to commence production in 2029, a representative for TPI told Fierce. The project will also create 225 permanent positions at the site over the next three years, plus approximately 500 construction jobs during the build-out phase, the representative explained. The new plant has also received a $10 million investment from the state itself, the representative added, explaining that TPI weighed more than 350 possible plant locations before settling on Philadelphia for its proximity to key infrastructure and the nearby life sciences ecosystem.Once the Washington expansion and new Philadelphia facility come online, TPI expects to increase its production capacity 20-fold and become the world’s top distributor of ac-225, according to a March 17 press release. “This new facility is a testament to the demand for actinium-225 as part of the growing industry which is transforming how cancer is treated,” Scott Claunch, TPI’s president, said in a statement. TerraPower President and CEO Chris Levesque added that the plant will “help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments.” There is heavy R&D interest in the field of radiopharmaceuticals, which wed a radioisotope with a targeting molecule to home in on and destroy cancerous tissue. Nuclear medicine can be used for diagnostic purposes, as well. Still, companies have seen limited commercial success with the class of drugs, excluding Novartis, which currently boasts two approved radioligand therapies in Lutathera and Pluvicto. The meds are cleared to treat neuroendocrine tumors and prostate cancer, respectively. Novartis’ pair of commercial radiopharmaceuticals utilize the radioisotope lutetium-177 (Lu-177), although Sven Van Den Berghe, CEO of Belgian radiopharmaceutical player PanTera, told Fierce in an interview last year that “[t]he next revolution is coming right after [Lu-177], which is actinium-225.” He noted that ac-225, which holds great promise in oncology treatment but has yet to make its way into a marketed product, requires a completely different production route than lutetium. PanTera is partnered with TPI. In the summer of 2023, the two companies joined forces to wed their production approaches with the goal of increasing global availability of ac-225. TPI’s Philadelphia outlay joins a growing roster of radiopharmaceutical manufacturing projects that have originated from suppliers, up-and-coming drug developers and Novartis itself. In fact, the Swiss drug giant outlined two new planned radiopharmaceutical manufacturing facilities in Florida and Texas in February, which fall under the broader $23 billion U.S. investment the company unveiled in 2025. With those new sites, Novartis will soon boast a total of five for radiopharmaceuticals in the U.S. Novartis is also looking at the potential of ac-225 and earlier this year struck a deal with Niowave for a scalable supply of the specialized ingredient. Niowave is supplying its ac-225 radioisotope to AstraZeneca as well, with the partners in December locking in a 10-year agreement. TPI has been striking actinium supply deals of its own, such as last June’s tie-up with Ratio Therapeutics to furnish the biotech with ac-225 for its pipeline of targeted cancer medicines.

18 Mar 2026

·www.biospace.com

TerraPower Commits $450M to Build Radioisotope Production Plant

iStock, f11photo Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis. TerraPower Isotopes has committed $450 million to build a manufacturing facility in Philadelphia, setting the company up to increase production capacity for a key radioisotope by 20-fold. The company, which was co-founded by Bill Gates, is working to increase availability of the alpha-emitting isotope actinium-225. Because actinium-225 emits more energy than lutetium-177, the beta-emitting isotope in Novartis’ Lutathera and Pluvicto, companies have identified the nuclear material as an enabler of next-generation radioligand therapies. Rising demand has stretched supply, leading Bristol Myers Squibb’s RayzeBio to pause a Phase 3 trial over a shortage of actinium-225 in 2024. The situation has led companies including TerraPower to invest in capacity to make actinium-225. Manufacturing Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies. February 17, 2026 · 4 min read · Nick Paul Taylor Read more Having initially served the market from Washington State, TerraPower announced Tuesday that it is establishing a presence on the East Coast by building a cGMP-compliant production facility in Philadelphia. Actinium-225 has a half-life of less than 10 days, making proximity to patients a key consideration when choosing the location of manufacturing plants. The Commonwealth of Pennsylvania, which is investing $10 million in the project, said TerraPower will create 225 full-time jobs in Philadelphia over the next three years. The staff will work at a 250,000-square-foot facility that TerraPower is leasing on the site of the former Philadelphia Energy Solutions refinery. The company expects to start making actinium-225 at the facility in 2029. TerraPower evaluated more than 350 locations in the U.S. and visited 49 sites in eight metropolitan areas before choosing Philadelphia’s Bellwether District as its East Coast base, according to its announcement. The radioisotope manufacturer has disclosed actinium-225 supply deals with companies including Aktis Oncology , Clarity Pharmaceuticals and Point Biopharma , which Eli Lilly bought for $1.4 billion in 2023. TerraPower also struck a deal with PanTera, a European company that supplies actinium-225 to Bayer. Historically, Oak Ridge National Laboratory met industry demand for actinium-225 through the decay of thorium-229 left over from nuclear weapons programs in the 1940s and 1950s. TerraPower, which was founded in 2018, and other companies invested in capacity as demand rose. BWXT Medical, Eckert & Ziegler, Ionetix, ITM, Niowave, NorthStar Medical Radioisotopes and Nusano are among the companies now supplying the isotope. The suppliers are supporting an expanding pipeline. With companies including AstraZeneca, BMS, Lilly and Novartis entering the space, the number of new clinical trials involving actinium-225 has surged since the start of last year.

AcquisitionPhase 3Radiation Therapy

06 Mar 2026

·www.fiercepharma.com

Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC

Kyowa Kirin's ill-fated OX40 autoimmune program, Sanofi and Sino Biopham's first-in-class licensing deal, and BioNTech and DualityBio's B7-H3 update made our news this week. Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. Sanofi is committing up to $1.5 billion for global rights to Sino Biopharm's first-in-class JAK/ROCK inhibitor, which has potential in graft-versus-host disease. With strong early-stage data in prostate cancer, BioNTech is moving a DualityBio-licensed B7-H3 antibody-drug conjugate into phase 3. And more.1. New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease programKyowa Kirin has decided to discontinue all clinical development of its anti-OX40 drug about a month after Amgen exited a partnership around the candidate, rocatinlimab. Two new cases of Kaposi’s sarcoma—one confirmed and one suspected—were reported on top of a previous case, drawing a “potential mechanistic link to OX40 pathway modulation,” according to the company.2. Sanofi strikes $1.5B global licensing deal for Sino Biopharm's first-in-class JAK/ROCK assetSanofi will pay $135 million upfront to obtain global rights to Sino Biopharm’s first-in-class JAK/ROCK inhibitor rovadicitinib, which was just approved in China in myelofibrosis. The drug’s “core value,” according to the seller, is in its potential in chronic graft-versus-host disease. The deal includes up to $1.395 billion in potential milestones. 3. BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rivalBioNTech’s DualityBio-partnered B7-H3 antibody-drug conjugate showed median radiographic progression-free survival of 11.3 months among heavily pretreated patients with metastatic castration-resistant prostate cancer, including some who had failed on Novartis’ Pluvicto. BioNTech is moving the drug, BNT324, into a phase 3 that’s half the size of a competing program from Merck & Co. and Daiichi Sankyo.4. Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinationsWith 3SBio’s PD-1xVEGF bispecific, partner Pfizer is aiming to beat the competition based on breadth of research, speed and novel combinations, the pharma’s oncology chief said. In less than a year since the agreement, Pfizer will have started 12 clinical trials of the drug, Pfizer’s Jeff Legos, Ph.D., told Fierce. Pfizer’s first phase 3 trials look similar to its competitors’, but the company is evaluating new combinations, including with its ADCs, he added.5. UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidateUCB is paying $80 million upfront for rights to a CD19xCD3 T-cell engager made by Antengene. The drug is slated to enter phase 1 testing in China and Australia by the end of March. Antengene is responsible for completing first-in-human studies before UCB takes over. The Chinese biotech is eligible to receive up to $1.1 billion in milestone payments.6. Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'Roche signed a memorandum of understanding with the South Korean government for the Swiss pharma to spend about $484 million in South Korea’s biopharma industry. The partnership will strengthen the country’s competitiveness “by establishing an ecosystem for global clinical trials and enhancing R&D capabilities for innovative medicines,” a Roche spokesperson said.Other News of Note:7. Padcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex8. Ono's Deciphera drops early-stage solid tumor drug for strategic reasons9. Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal10. BioDuro enters Taiwan joint venture, adding commercial API plant to production network11. TCE biotech Candid scores Nasdaq listing via reverse merger with rare-disease-focused Rallybio12. Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs13. GLP-1 player QL Biopharm raises $73M in series C (Fundraising tracker)14. Daiichi Sankyo pens pact with Germany's Gaia to sell digital therapeutic for high cholesterol

Phase 3License out/inPhase 1ADC

100 Deals associated with Lutetium (177 Lu) Vipivotide Tetraxetan

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
PSMA-Positive Castration-Resistant Prostatic Cancer	United States	Novartis Pharmaceuticals Corp.	23 Mar 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone-dependent prostate cancer	NDA/BLA	China	Novartis Pharma Schweiz AG	04 Nov 2025
Hormone-dependent prostate cancer	NDA/BLA	China	Advanced Accelerator Applications (Italy) Srl	04 Nov 2025
Hormone-dependent prostate cancer	NDA/BLA	China	Beijing Novartis Pharma Co. Ltd.	04 Nov 2025
Oligometastatic Prostate Carcinoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	China	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Japan	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Australia	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Austria	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	12 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2026 \| Company_Website Manual	Not Applicable	Metastatic castration-resistant prostate cancer	442	Lu-PSMA-617	sfecwuyxpj(cmafxyohbt) = glvhsoicrm wbnemnlikk (fqvytobrox, 7.2 - 10.1) View more	Positive	26 Feb 2026
				Lu-PSMA-617 (Subsequent therapy Taxane)	sfecwuyxpj(cmafxyohbt) = zmmwkjutnx wbnemnlikk (fqvytobrox, 5.9 - 9.4)
ASCO_GU2026	Not Applicable	Metastatic castration-resistant prostate cancer	213	177Lu-PSMA-617	wdemhqmthz(leyyxlcpvl) = CKD stage distribution at baseline and 12 months are shown in the Table. atzmozjllk (dxqyarmsnf )	Positive	26 Feb 2026
ASCO_GU2026	Not Applicable	Metastatic castration-resistant prostate cancer	1,880	177Lu-PSMA-617 with concomitant ARPI	lnqvrxoxdy(dlimdzqwcc) = wkrxmbgyob adqacibpqr (qoaqxgcyol, 11.7 - 21.3)	Positive	26 Feb 2026
				177Lu-PSMA-617 without concomitant therapy	lnqvrxoxdy(dlimdzqwcc) = enlslqweuh adqacibpqr (qoaqxgcyol, 11.5 - 13.6)
ASCO_GU2026	Not Applicable	Castration-Resistant Prostatic Cancer	1,002	177Lu-PSMA 617 (Treatment-naïve)	kzdsvjlxdy(hqsrnknxed) = lnykoiogga mmfgomzweh (zamfhqgrso, 13.3 - 16.8) View more	Positive	26 Feb 2026
				177Lu-PSMA 617 (Previously treated)	kzdsvjlxdy(hqsrnknxed) = xnvyvrfyhi mmfgomzweh (zamfhqgrso, 13.3 - 16.8) View more
NCT07047118 (LuxAR-02, ASCO_GU2026)	Phase 2	Metastatic castration-resistant prostate cancer prostate-specific membrane antigen (PSMA)-positive	15	Luxdegalutamide 100 mg QD + 177Lu-PSMA-617	hyvaiqrkga(tbrbjuvwww) = ridahxwyym yfnsxrxfly (vadxhalacg ) View more	Positive	26 Feb 2026
				Luxdegalutamide 300 mg QD + 177Lu-PSMA-617	hyvaiqrkga(tbrbjuvwww) = pnosqehlcg yfnsxrxfly (vadxhalacg ) View more
NCT05670106 (ASCO_GU2026)	Phase 2	Metastatic castration-resistant prostate cancer prostate-specific membrane antigen (PSMA)-positive	59	177Lu-PSMA-617 + Best Standard of Care (BSoC)	mivvvlevza(bgwwgctatz) = iywtajnmpl yiqabszepv (vppgguxkwk, 23.5 - 61.1) View more	Positive	26 Feb 2026
ASCO_GU2026	Not Applicable	Metastatic castration-resistant prostate cancer	163	Lutetium-177-PSMA-617	zntrpimeuk(xsvlldgiln) = A decline in BMI during treatment with 177Lu–PSMA-617 is associated with shortened PFS and OS. nqcrwzjmji (kdsbyxkwan ) View more	Negative	26 Feb 2026
NEWS \| Company_Website Manual	Not Applicable	Metastatic castration-resistant prostate cancer	500	Pluvicto (treated with ≥1 ARPI)	qwxizuqaff(qorwhlsmdn) = rnqcqlcvuh lvwlixutcf (wljjkoovza, 11.7 - 14.7) View more	Positive	24 Feb 2026
				Pluvicto (treated with only 1 ARPI)	qwxizuqaff(qorwhlsmdn) = yhavyeeplv lvwlixutcf (wljjkoovza, 11.7 - 18.6) View more
ESMO_ASIA2025	Not Applicable	Metastatic Prostate Carcinoma	18	[177Lu]Lu-PSMA-617	izsbnsnckq(hlifrxrnlj) = vncxcatlxw vesxojogws (mhvmmoclkm ) View more	Positive	05 Dec 2025
NCT06783348 (RENALUT, Pubmed \| Eur Urol Oncol)	Phase 2	Metastatic Clear Cell Renal Cell Carcinoma PSMA-positive	48	[177Lu]Lu-PSMA-617	nakjvymvil(tkjsygjqdu) = The most common grade ≥3 adverse events were neutropenia (15%, mainly grade 3), fatigue (10%), and thrombocytopenia (8%) sfxoyjhotp (ytfmaynpfz ) View more	Positive	01 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lutetium (177 Lu) Vipivotide Tetraxetan

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation